norleual

Norleual is a synthetic peptide analog of angiotensin IV that acts as a potent antagonist of hepatocyte growth factor (HGF). It is designed to mimic the hinge region of HGF, thereby competitively inhibiting HGF dimerization, which is a critical step for the activation of the c-Met receptor. By blocking the HGF/c-Met signaling pathway, Norleual inhibits cellular processes such as proliferation, migration, and invasion in various cancer types, including pancreatic cancer. It was developed by researchers at Washington State University and has shown picomolar affinity for HGF, effectively attenuating the cellular responses of pancreatic cancer cells to HGF-induced activation.

Other names

Nle-Tyr-Ile-ψ-(CH2-NH2)3-4-His-Pro-Pheangiotensin IV analog